NumFin

Ultragenyx Pharmaceutical Inc.

符号: RARE

NASDAQ

43.01

USD

今天的市场价格

  • -5.9104

    市盈率

  • 0.0654

    PEG比率

  • 3.54B

    MRK市值

  • 0.00%

    DIV收益率

Ultragenyx Pharmaceutical Inc. (RARE) 财务报表

Download
年度季度
线性对数
在图表中，您可以看到 的动态默认数字 Ultragenyx Pharmaceutical Inc. (RARE). 的默认数据。公司收入显示 121.382 M 的平均值，即 3.116 % 增长率。整个期间的平均毛利润为 113.242 M，即 3.078 %. 平均毛利率为 0.588 %. 公司去年的净收入增长率为 -0.142 %，等于 -0.584 % % 整个公司历史的平均增长率.,

年度季度
10Y20Y30Y40Y

资产负债表

深入分析 Ultragenyx Pharmaceutical Inc. 的财务轨迹，我们可以看到其平均资产增长率。有趣的是，这一增长率为 ，反映了公司的高点和低点。与季度相比，这一数字调整为0. 回顾过去一年，总资产变化为 -0.035. 在流动资产领域，RARE 的报告货币为732.184. 这些资产中的很大一部分，即 777.11 是现金和短期投资。与去年的数据相比，该部分的变化率为-0.133%. 公司的长期投资虽然不是其重点，但以报告货币计算的199.901（如果有的话）为199.901。这表明与上一报告期相比，29.385% 的差异反映了公司的战略转变. 公司的债务概况显示，以报告货币计算的长期债务总额为 30.574. 这一数字表明，0.366% 的年同比变化. 股东权益总额所体现的股东价值是以报告货币计算的 275.414. 这方面的年同比变化率为 -0.219%. 深入了解公司财务信息后，会发现更多细节。应收账款净额的估值为73.39，存货估值为 33.97，商誉估值为 44.41（如有. 无形资产总额（如果有）按 166.27 估值.

common:word.in-mln

USD
Growth
TTM2023202220212020201920182017201620152014201320122011

balance-sheet.row.cash-and-short-term-investments

2271.64777.1896.7999.1
1212
760.4
459.7
244.5
498.1
437
187.5
53.4
86.2
10.6

balance-sheet.row.short-term-investments

1482.9363.6614.8432.6
488
321.6
346.3
134
219
343.4
163.2
46
0
0

balance-sheet.row.net-receivables

323.6373.440.428.4
23.1
32.8
12.7
5.2
0
0
0
0
0
0.1

balance-sheet.row.inventory

129.933426.816.2
13
11.5
7.1
0.8
0
0
0
0
0
0

balance-sheet.row.other-current-assets

-638.48-777.168.9-187.2
47.1
46.2
42.9
29.2
21.5
13.2
5.9
1.8
0.3
0.2

balance-sheet.row.total-current-assets

2554.45732.2883.9856.6
1295.3
851
522.4
244.5
498.1
450.2
187.5
55.2
86.4
11

balance-sheet.row.property-plant-equipment-net

1207.13290.6285.7176.2
114
74.7
20
21.8
17.1
7.4
3
1.3
1.4
0.8

balance-sheet.row.goodwill

177.6244.444.444.4
44.4
44.4
44.4
44.4
0
0
0
0
0
0

balance-sheet.row.intangible-assets

646.86166.3160.1130.8
131.1
129
129.2
141.5
0
0
0
0
0
0

balance-sheet.row.goodwill-and-intangible-assets

824.48210.7204.5175.2
175.5
173.4
173.6
186
0
0
0
0
0
0

balance-sheet.row.long-term-investments

436.17199.9154.5293.9
165.9
32.9
0
10
118
99.3
0
0
0
0

balance-sheet.row.tax-assets

80.9866.18.9
33.3
7.7
0
25.1
0
0
0
0
0
0

balance-sheet.row.other-non-current-assets

244.3451.710.711.6
-24.5
-4.2
3.5
3.4
-92.5
2.7
7.4
3.1
0.5
0.4

balance-sheet.row.total-non-current-assets

2793.09758.8661.5665.8
464.3
284.5
197.2
246.3
42.5
109.4
10.5
4.4
1.9
1.2

balance-sheet.row.other-assets

0000
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-assets

5347.5414911545.41522.4
1759.6
1135.5
719.6
490.8
540.6
559.6
198
59.6
88.3
12.1

balance-sheet.row.account-payables

158.5642.143.317.1
12.9
12.9
12.3
8.9
5.4
2.9
4.9
1.4
1.2
0.3

balance-sheet.row.short-term-debt

91.0212.611.811.1
9
7.2
0
0
0
0
0
0
0
0

balance-sheet.row.tax-payables

0000
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.long-term-debt-total

928.730.619.830.9
39.3
29.8
0
0
0
0
0
0
0
0

Deferred Revenue Non Current

1736.75862.301.5
7.3
0
0
0
0
0
0
0
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

123.45---
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.other-current-liab

410.6529.2204.7145.6
108.5
83.2
62.5
56.1
54.9
25
7.7
4.5
2
0.7

balance-sheet.row.total-non-current-liabilities

3746.75935.2931.7418.5
415.6
378.4
35.9
36.3
6.4
0.6
0.5
3.6
0.8
0.5

balance-sheet.row.other-liabilities

0000
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.capital-lease-obligations

108.9443.231.642
48.2
37
0
0
0
0
0
0
0
0

balance-sheet.row.total-liab

4771.121215.61193599.8
605.2
481.7
110.7
107.3
66.7
28.5
13
9.5
4
1.5

balance-sheet.row.preferred-stock

0000
0
0
0
0
0.1
0
198
124.9
111.4
18.6

balance-sheet.row.common-stock

0.310.10.10.1
0.1
0.1
0.1
0
0
0
0
0
0
0

balance-sheet.row.retained-earnings

-13315.3-3387.7-2781-2073.6
-1619.6
-1433
-1030.3
-832.7
-530.5
-284.7
-139
-74.8
-27.1
-8.2

balance-sheet.row.accumulated-other-comprehensive-income-loss

-1.790.6-6.6-1.4
0.7
-0.1
-0.6
-5.7
0.9
-0.9
-0.2
0
-0.4
0

balance-sheet.row.other-total-stockholders-equity

13893.213662.331402997.5
2773.2
2086.9
1639.8
1222.1
1003.5
816.7
126.2
0
0.4
0.2

balance-sheet.row.total-stockholders-equity

576.42275.4352.5922.6
1154.4
653.8
608.9
383.5
474
531.1
184.9
50.1
84.3
10.6

balance-sheet.row.total-liabilities-and-stockholders-equity

5347.5414911545.41522.4
1759.6
1135.5
719.6
490.8
540.6
559.6
198
59.6
88.3
12.1

balance-sheet.row.minority-interest

0000
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-equity

576.42275.4352.5922.6
1154.4
653.8
608.9
-
-
-
-
-
-
-

balance-sheet.row.total-liabilities-and-total-equity

5347.54---
-
-
-
-
-
-
-
-
-
-

Total Investments

1852.69563.5620.3726.5
653.9
354.6
346.3
144
337
442.7
163.2
46
0
0

balance-sheet.row.total-debt

1013.1443.231.642
48.2
37
0
0
0
0
0
0
0
0

balance-sheet.row.net-debt

506.37-170.4-101.4-265.6
-665.3
-396.6
-113.4
-100.5
-161.1
-93.6
-24.3
-7.4
-86.2
-10.6

现金流量表

在 Ultragenyx Pharmaceutical Inc. 的财务状况中，自由现金流在过去一段时间内发生了显著变化，呈现出 0.010 的转变。该公司最近通过发行 379.75 扩大了股本，与上一年相比出现了17.143 的差异. 有趣的是，公司的部分股票，特别是 0，是由公司自己回购的。这一举动导致0.000 比上一年有所变化。同时，以报告货币计算，公司的应付账款目前为 2.38. 公司的投资活动产生了现金使用净额，按报告货币计算达到168000000.000. 与上一年相比， -1.576 发生了变化. 在同一时期，公司记录了 26.01, -2.55 和 0，这对于了解公司的投资和还款策略具有重要意义. 公司的融资活动导致使用的现金净额为0.000，同比差异为0.000. 此外，公司还将0 用于向股东分红。与此同时，该公司还采取了其他财务措施，即 8.39，这也对其在此期间的现金流产生了重大影响. 这些组成部分合在一起，全面反映了公司的财务状况和现金流管理的战略方针。

common:word.in-mln

USD
Growth
TTM2023202220212020201920182017201620152014201320122011

cash-flows.row.net-income

-613.35-606.6-707.4-454
-186.6
-402.7
-197.6
-302.1
-245.9
-145.6
-59.8
-35.1
-16.3
-6.8

cash-flows.row.depreciation-and-amortization

29.612618.213.2
12.3
8.5
19.5
5.8
3.4
1.4
0.7
0.4
0.3
0

cash-flows.row.deferred-income-tax

-143.91-1.6-1.648.7
-169.8
-18.9
-167.7
-16.2
6.2
0
0
0
0
0

cash-flows.row.stock-based-compensation

140.2135.2130.4105
85.7
82
80.1
68
48.3
24.9
5.4
0.7
0.9
0.3

cash-flows.row.change-in-working-capital

-32.76-15.160.2-63.2
104.7
-15.9
-24.8
-20.2
26.3
7.7
2.2
-1.5
2.3
0.5

cash-flows.row.account-receivables

-45.18-22.8-12.1-5.4
9.8
-20.1
-7.6
0
0
0
0
0
0
0

cash-flows.row.inventory

-9.2-6.9-9.7-3.1
-1.3
-4.5
-5.3
0
0
0
0
0
0
0

cash-flows.row.account-payables

-0.412.487.42.8
29.6
20.6
3.4
3.5
2.5
-2
3.2
0.2
0.9
0.3

cash-flows.row.other-working-capital

22.0412.2-5.4-57.5
66.6
-12
-15.3
-23.7
23.8
9.7
-1
-1.8
1.5
0.2

cash-flows.row.other-non-cash-items

228.72-12.7119.811.7
21.5
1.7
-0.2
10.9
0.7
5.6
6.9
4.3
0.3
0.3

cash-flows.row.net-cash-provided-by-operating-activities

-508.67000
0
0
0
0
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

-34.94-46.8-146.1-73.1
-43.9
-24.8
-4.1
-2.8
-10.2
-5
-2.1
-0.4
-1.1
-0.5

cash-flows.row.acquisitions-net

0-2.5-750
0
-11.8
0
-142.8
0
0
0
0
0
0

cash-flows.row.purchases-of-investments

-486.29-526.4-614.7-1012.2
-850.3
-707.2
-509.8
-230.5
-442.5
-624.2
-209
-64
0
0

cash-flows.row.sales-maturities-of-investments

675.52746.2545.1890.9
720.6
719
310.2
431.6
543.8
338.4
88
16.6
0
0

cash-flows.row.other-investing-activites

-0.66-2.5-0.8-0.9
-5.6
11.8
170.3
0.9
-1.2
-1.5
-0.3
0
-0.1
-0.4

cash-flows.row.net-cash-used-for-investing-activites

151.13168-291.7-195.4
-179.1
-13
-33.3
56.4
89.9
-292.4
-123.4
-47.7
-1.2
-0.9

cash-flows.row.debt-repayment

00-490.90
0
-314.2
0
-4.9
0
0
0
0
0
0

cash-flows.row.common-stock-issued

354.26379.810.878.9
511.2
355.2
309
132
79.5
467.6
189.3
0.2
0.1
0

cash-flows.row.common-stock-repurchased

-0.06000
0
0
0
0
0
0
0
0
0
0

cash-flows.row.dividends-paid

0000
0
0
0
0
0
0
-4.3
0
0
0

cash-flows.row.other-financing-activites

34.558.4981.339.6
89.1
638.3
27.8
9.3
59.2
0
0
0
89.1
17.3

cash-flows.row.net-cash-used-provided-by-financing-activities

388.81388.1501.2118.6
600.3
679.3
336.9
136.3
138.7
467.6
185
0.2
89.2
17.3

cash-flows.row.effect-of-forex-changes-on-cash

-0.430.5-1.1-1.2
1.1
-0.2
-0.5
0.5
-0.1
0
0
0
0
0

cash-flows.row.net-change-in-cash

34.8985.6-172-416.7
290.1
320.7
12.5
-60.6
67.6
69.2
16.9
-78.8
75.5
10.6

cash-flows.row.cash-at-end-of-period

524.23219.4137.6309.6
726.3
436.2
115.5
100.5
161.1
93.6
24.3
7.4
86.2
10.6

cash-flows.row.cash-at-beginning-of-period

489.34133.8309.6726.3
436.2
115.5
103
161.1
93.6
24.3
7.4
86.2
10.6
0.1

cash-flows.row.operating-cash-flow

-508.67-474.8-380.5-338.7
-132.2
-345.4
-290.6
-253.8
-161
-106
-44.6
-31.2
-12.5
-5.8

cash-flows.row.capital-expenditure

-34.94-46.8-146.1-73.1
-43.9
-24.8
-4.1
-2.8
-10.2
-5
-2.1
-0.4
-1.1
-0.5

cash-flows.row.free-cash-flow

-543.61-521.6-526.6-411.8
-176.1
-370.2
-294.6
-256.6
-171.2
-110.9
-46.8
-31.6
-13.6
-6.4

利润表行

Ultragenyx Pharmaceutical Inc. 的收入与上期相比变化了 0.195%。据报告, RARE 的毛利润为 389.04。该公司的营业费用为 958.25，与上年相比变化了 -2.610%. 折旧和摊销费用为 26.01，与上一会计期间相比变化了 1.735%. 营业费用报告为 958.25，显示-2.610% 的同比变化。 销售和营销费用为 0, 其中 0.000% 与上年相比发生了变化。 基于近期数据的EBITDA为 0，同比增长0.123%. 营业收入为 -569.21，与上年相比变化了-0.123%. 净利润的变化率为 -0.142%。去年的净收入为-606.64.

common:word.in-mln

USD
Growth
TTM2023202220212020201920182017201620152014201320122011

income-statement-row.row.total-revenue

442.59434.2363.3351.4
271
103.7
51.5
2.6
0.1
0
0
0
0
0

income-statement-row.row.cost-of-revenue

59.3345.228.316
6.1
9
1.1
0
0
0
0
0
0
0

income-statement-row.row.gross-profit

383.26389335335.4
264.9
94.7
50.3
2.6
0.1
0
0
0
0
0

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.research-development

652.39---
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

0---
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-expenses

5.24-0.39.50.2
7.6
12.5
4
10.6
2.2
-0.2
-3
-3
-0.3
0

income-statement-row.row.operating-expenses

963.71958.2983.9717.1
595
518.9
421.7
331.6
248.1
147.7
56.8
32.3
16
6.6

income-statement-row.row.cost-and-expenses

1023.041003.51012.2733.1
601.1
527.9
422.9
331.6
248.1
147.7
56.8
32.3
16
6.6

income-statement-row.row.interest-income

29.2226.711.11.9
7
13.2
9.5
4.1
3.8
2.3
0.6
0.2
0
0

income-statement-row.row.interest-expense

34.52664329.4
33.3
1.1
0
0
0
0
0
0
0
0.3

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

-7.69-39.3-52.8-71.2
144.8
24.7
174.3
10.6
2.2
-0.2
-3
-3
-0.3
0

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

5.24-0.39.50.2
7.6
12.5
4
10.6
2.2
-0.2
-3
-3
-0.3
0

income-statement-row.row.total-operating-expenses

-7.69-39.3-52.8-71.2
144.8
24.7
174.3
10.6
2.2
-0.2
-3
-3
-0.3
0

income-statement-row.row.interest-expense

34.52664329.4
33.3
1.1
0
0
0
0
0
0
0
0.3

income-statement-row.row.depreciation-and-amortization

27.61269.50.2
7.6
12.5
19.5
5.8
3.4
1.4
0.7
0.4
0.3
0

income-statement-row.row.ebitda-caps

-538.27---
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.operating-income

-580.45-569.2-648.9-381.7
-330.1
-424.2
-371.4
-328.9
-248
-147.7
-56.8
-32.3
-16
-6.6

income-statement-row.row.income-before-tax

-615.22-608.5-701.7-453
-185.4
-399.4
-197.1
-318.3
-245.8
-145.6
-59.8
-35.1
-16.3
-6.8

income-statement-row.row.income-tax-expense

-1.86-1.85.71
1.2
3.3
0.5
-16.2
0
-2.3
-0.7
-3
-0.3
0.2

income-statement-row.row.net-income

-613.35-606.6-707.4-454
-186.6
-402.7
-197.6
-302.1
-245.9
-145.6
-59.8
-35.1
-16.3
-6.8
类似股票
您可能还对以下内容感兴趣：
SRNE
Sorrento Therapeutics, Inc..
0.016 USD
NASDAQ
MRVI
Maravai LifeSciences Holdings, Inc..
9.01 USD
NASDAQ
CMRA
Comera Life Sciences Holdings, Inc..
0.0212 USD
NASDAQ
GUBRA.CO
Gubra A/S.
309 DKK
CPH
T5O.DE
CytoTools AG.
0.468 EUR
XETRA
6826.HK
Shanghai Haohai Biological Technology Co., Ltd..
42.4 HKD
HKSE
PPBT
Purple Biotech Ltd..
0.67 USD
NASDAQ

常见问题

什么是 Ultragenyx Pharmaceutical Inc. (RARE) 总资产是多少？

Ultragenyx Pharmaceutical Inc. (RARE) 总资产为 1491013000.000.

什么是企业年收入？

年收入为 236225000.000.

企业利润率是多少？

公司利润率为 0.866.

什么是公司自由现金流？

自由现金流为 -6.450.

什么是企业净利润率？

净利润率为 -1.386.

企业总收入是多少？

总收入为 -1.311.

什么是 Ultragenyx Pharmaceutical Inc. (RARE) 净利润？{{符号}}净利润（净收入）是多少？

净利润（净收入）为 -606639000.000.

公司总债务是多少？

债务总额为 43169000.000.

营业费用是多少？

运营支出为 958248000.000.

公司现金是多少？

企业现金为 118554000.000.